Skip to content
Screener

AngioDynamics ANGO Q4 2026 Annual earnings

Reported July 14, 2026 · Before market open

Revenue$86.6MBeat by $6.4M
EPS-$0.27Miss by $0.16
Revenue estimate$80.2M
EPS estimate-$0.11
“Our strong fourth quarter capped a year of consistent execution at AngioDynamics, Full-year Med Tech growth of more than 18% reflects the continued progress of our strategic transformation, as our innovative platform technologies across cardiology and interventional oncology took share in large, fast-growing global markets. Combined with our operational discipline, that growth drove continued profitability even as we absorbed tariff-related headwinds.”
Jim Clemmer

Next report

Oct 1, 2026 (in 2 months)
Revenue estimate$80.5M
EPS estimate-$0.09

Financials

Q4 2026

Income statement

See full
Revenue$86.6M+8.0%
Gross profit$46.8M+10.8%
Operating income-$10.2M-76.1%
Net income-$11.4M-88.5%
EPS (diluted)-$0.27-80.0%

Balance sheet

See full
Cash & equivalents$53.9M-3.6%
Total debt$11.0M+8.0%
Total equity$170.8M-6.6%
Total assets$267.2M-4.6%

Cash flow

See full
Operating cash flow$17.5M—
CapEx$413.0K-46.8%
Free cash flow$17.0M—

Valuation & ratios

Valuation

as of 08/04/26
See full
Market cap$611.31M+78.0%
Enterprise value$568.4M+90.5%
P/S1.9×+0.7×

Profitability

See full
Gross margin54.6%+0.7pp
Operating margin-12.5%-1.0pp
Net margin-11.5%-0.1pp
FCF margin0.2%—

Returns & leverage

See full
Return on equity-20.8%+4.8pp
Debt / equity0.1×0.0×
Current ratio2.2×0.0×

Segments

By product

See full
Med Device$44.8M—
Med Tech$41.8M—

FAQ

When did AngioDynamics report Q4 2026 earnings?
AngioDynamics (ANGO) reported Q4 2026 earnings on July 14, 2026 before market open.
What were AngioDynamics's Q4 2026 revenue and EPS?
AngioDynamics reported revenue of $86.6M and eps of $-0.27 for Q4 2026.
Did AngioDynamics beat estimates in Q4 2026?
Revenue beat the consensus estimate of $80.2M by $6.4M. EPS missed the consensus estimate of $-0.11 by $0.16.
How did AngioDynamics's Q4 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 8.0% from $80.2M a year earlier and eps declined 800.0% from $-0.03.
Where can I find AngioDynamics's Q4 2026 SEC filings?
You can read the 8-K earnings release (0001140361-26-028368) and the 10-K periodic report (0001628280-26-048138) directly on SEC EDGAR. The filing index links above go to sec.gov.